Mga Batayang Estadistika
| CIK | 1459266 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to ZS Pharma, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| February 16, 2016 |
ZSPH / ZS Pharma, Inc. / HIGHBRIDGE CAPITAL MANAGEMENT LLC Passive Investment SC 13G/A 1 p16-0327sc13ga.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* ZS Pharma, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 98979G105 (CUSIP Number) December 31, 2015 (Date of event which requires filing of this statement) Check the appropriate box to des |
|
| February 9, 2016 |
ZSPH / ZS Pharma, Inc. / DEVON PARK BIOVENTURES LP - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ZS Pharma, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 98979G105 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| December 28, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-36489 ZS Pharma, Inc. (Exact name of registrant as specified in its cha |
|
| December 21, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) ZS PHARMA, INC. (Name of Subject Company) ZANZIBAR ACQUISITION CORP. ZENECA, INC. ASTRAZENECA PLC (Names of Filing Persons ? Offeror) Common Stock, Par Value $0.001 Per Share (Title of Class of Securit |
|
| December 21, 2015 |
ZSPH / ZS Pharma, Inc. / Zeneca, Inc. - FORM SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) UNDER THE SECURITIES AND EXCHANGE ACT OF 1934 (Amendment No. 2) ZS Pharma, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 98979G 105 (CUSIP |
|
| December 18, 2015 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 3) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 ZS PHARMA, INC. (Name of Subject Company) ZS PHARMA, INC. (Name of Person Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 98979G105 (CUSIP Numb |
|
| December 17, 2015 |
S-8 POS As filed with the Securities and Exchange Commission on December 17, 2015 Registration No. |
|
| December 17, 2015 |
AMENDED AND RESTATED BYLAWS OF ZS PHARMA, INC. * * * * * Article 1 Offices EX-3.2 3 dp61924ex0302.htm EXHIBIT 3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF ZS PHARMA, INC. * * * * * Article 1 Offices Section 1.01. Registered Office. The registered office of the Corporation shall be in the City of Wilmington, County of New Castle, State of Delaware. Section 1.02. Other Offices. The Corporation may also have offices at such other places both within and without the State o |
|
| December 17, 2015 |
SC TO-T/A 1 dp61919sctota2.htm FORM SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) ZS PHARMA, INC. (Name of Subject Company) ZANZIBAR ACQUISITION CORP. ZENECA, INC. ASTRAZENECA PLC (Names of Filing Persons – Offeror) Common Stock, Par Val |
|
| December 17, 2015 |
AstraZeneca COMPLETES ACQUISITION OF ZS PHARMA EX-99.(A)(5)(VII) 2 dp61919exa5vii.htm EXHIBIT (A)(5)(VII) Exhibit (a)(5)(vii) AstraZeneca COMPLETES ACQUISITION OF ZS PHARMA AstraZeneca announced today the successful completion of the tender offer for all of the outstanding shares of ZS Pharma (NASDAQ: ZSPH) and the subsequent acquisition of ZS Pharma as previously announced in November. The transaction strengthens AstraZeneca’s cardiovascular |
|
| December 17, 2015 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ZS PHARMA, INC. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ZS PHARMA, INC. FIRST: The name of the corporation is ZS Pharma, Inc. (the ?Corporation?). SECOND: The address of its registered office in the State of Delaware is Corporation Trust Center, 1209 Orange Street, City of Wilmington, County of New Castle, Delaware 19801. The name of its registered agent at such address is The Corporation |
|
| December 17, 2015 |
AstraZeneca COMPLETES ACQUISITION OF ZS PHARMA EX-99.1 4 dp61924ex9901.htm EXHIBIT 99.1 Exhibit 99.1 AstraZeneca COMPLETES ACQUISITION OF ZS PHARMA AstraZeneca announced today the successful completion of the tender offer for all of the outstanding shares of ZS Pharma (NASDAQ: ZSPH) and the subsequent acquisition of ZS Pharma as previously announced in November. The transaction strengthens AstraZeneca’s cardiovascular and metabolic disease (CV |
|
| December 17, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2015 ZS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36489 26-3305698 (State or other jurisdiction of incorporation) (Commission File |
|
| December 17, 2015 |
S-8 POS As filed with the Securities and Exchange Commission on December 17, 2015 Registration No. |
|
| December 17, 2015 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 2) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 ZS PHARMA, INC. (Name of Subject Company) ZS PHARMA, INC. (Name of Person Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 98979G105 (CUSIP Numb |
|
| November 25, 2015 |
SC TO-T/A 1 dp61390sctota1.htm FORM SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) ZS PHARMA, INC. (Name of Subject Company) ZANZIBAR ACQUISITION CORP. ZENECA, INC. ASTRAZENECA PLC (Names of Filing Persons – Offeror) Common Stock, Par Val |
|
| November 24, 2015 |
SC 14D9/A 1 d92415dsc14d9a.htm SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 1) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 ZS PHARMA, INC. (Name of Subject Company) ZS PHARMA, INC. (Name of Person Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Se |
|
| November 24, 2015 |
ZS PHARMA, INC. Information about Stock Options, RSUs And ESPP Shares November 24, 2015 Exhibit (a)(1)(H) ZS PHARMA, INC. Information about Stock Options, RSUs And ESPP Shares November 24, 2015 You are receiving this notice because you hold Stock Options, Restricted Stock Units (RSUs) and/or you are a participant in the current purchase period under our Employee Stock Purchase Plan (ESPP). Below is a description of how your Options and RSUs and the ESPP will be treated in connection |
|
| November 20, 2015 |
ZSPH / ZS Pharma, Inc. / Zeneca, Inc. - FORM SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) UNDER THE SECURITIES AND EXCHANGE ACT OF 1934 (Amendment No. 1) ZS Pharma, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 98979G 105 (CUSIP |
|
| November 19, 2015 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ZS Pharma, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 98979G105 (CUSIP Number) November 9, 2015 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which |
|
| November 18, 2015 |
AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER Exhibit (d)(2) EXECUTION VERSION AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER THIS AMENDMENT NO. 1 to Agreement and Plan of Merger (this “Amendment”) is entered into as of November 17, 2015, among Zeneca, Inc., a Delaware corporation (“Parent”), Zanzibar Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and ZS Pharma, Inc., a Delaware corporation |
|
| November 18, 2015 |
EX-99.(A)(1)(IV) 5 d81601dex99a1iv.htm EX(A)(1)(IV) Exhibit (a)(1)(iv) Offer to Purchase for Cash All Outstanding Shares of Common Stock of ZS Pharma, Inc. at $90.00 Net per Share Pursuant to the Offer to Purchase Dated November 18, 2015 by Zanzibar Acquisition Corp. a wholly owned subsidiary of Zeneca, Inc. a wholly owned subsidiary of AstraZeneca PLC THE OFFER AND WITHDRAWAL RIGHTS EXPIRE AT 12: |
|
| November 18, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 ZS PHARMA, INC. (Name of Subject Company) ZANZIBAR ACQUISITION CORP. ZENECA, INC. ASTRAZENECA PLC (Names of Filing Persons?Offeror) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 98979G 105 (Cus |
|
| November 18, 2015 |
Schedule 14D-9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 18, 2015 |
Exhibit (a)(1)(vi) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| November 18, 2015 |
EX-99.(A)(1)(V) 6 d81601dex99a1v.htm EX-(A)(1)(V) Exhibit (a)(1)(v) Offer to Purchase for Cash All Outstanding Shares of Common Stock of ZS Pharma, Inc. at $90.00 Net per Share Pursuant to the Offer to Purchase Dated November 18, 2015 by Zanzibar Acquisition Corp. a wholly owned subsidiary of Zeneca, Inc. a wholly owned subsidiary of AstraZeneca PLC THE OFFER AND WITHDRAWAL RIGHTS EXPIRE AT 12:00 |
|
| November 18, 2015 |
Exhibit (a)(1)(ii) LETTER OF TRANSMITTAL to Tender Shares of Common Stock of ZS Pharma, Inc. |
|
| November 18, 2015 |
CONFIDENTIALITY AGREEMENT (Mutual Disclosure) EX-99.(D)(3) 9 d81601dex99d3.htm EX-(D)(3) Exhibit (d)(3) CONFIDENTIALITY AGREEMENT (Mutual Disclosure) THIS CONFIDENTIALITY AGREEMENT (the “Agreement”) is made and entered into as of September 23, 2015 (the “Effective Date”) by and between ZS Pharma, Inc., with principal offices located at 508 Wrangler Drive, Suite 100, Coppell, TX 75019 (“ZS Pharma”) and AstraZeneca Pharmaceuticals LP with princ |
|
| November 18, 2015 |
AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER EX-99.(e)(2) Exhibit (e)(2) EXECUTION VERSION AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER THIS AMENDMENT NO. 1 to Agreement and Plan of Merger (this ?Amendment?) is entered into as of November 17, 2015, among Zeneca, Inc., a Delaware corporation (?Parent?), Zanzibar Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (?Merger Sub?), and ZS Pharma, Inc., a Delaware |
|
| November 18, 2015 |
Exhibit (a)(1)(iii) NOTICE OF GUARANTEED DELIVERY to Tender Shares of Common Stock of ZS Pharma, Inc. |
|
| November 18, 2015 |
Table of Contents Exhibit (a)(1)(i) Offer to Purchase for Cash All Outstanding Shares of Common Stock of ZS Pharma, Inc. |
|
| November 13, 2015 |
EX-99.1 2 dp61155ex9901.htm EXHIBIT 1 Exhibit 1 EXECUTION COPY AGREEMENT AND PLAN OF MERGER AMONG ZENECA, INC., ZANZIBAR ACQUISITION CORP. AND ZS PHARMA, INC. Dated as of November 5, 2015 TABLE OF CONTENTS Page Article I THE OFFER 2 Section 1.01 The Offer 2 Section 1.02 Company Action 4 Article II THE MERGER 5 Section 2.01 The Merger 5 Section 2.02 Consummation of the Merger 5 Section 2.03 Effects |
|
| November 13, 2015 |
ZSPH / ZS Pharma, Inc. / Zeneca, Inc. - FORM SC 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) UNDER THE SECURITIES AND EXCHANGE ACT OF 1934 ZS Pharma, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 98979G 105 (CUSIP Number) Adiah Fer |
|
| November 13, 2015 |
Exhibit 3 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of stock of ZS Pharma, Inc. |
|
| November 13, 2015 |
EX-99.2 3 dp61155ex9902.htm EXHIBIT 2 Exhibit 2 Execution Version Tender and Support Agreement This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of November 5, 2015, is entered into by and among Zeneca, Inc., a Delaware corporation (“Parent”), Zanzibar Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and each of the persons set forth on |
|
| November 10, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 ZS Pharma, Inc. (Name of Subject Company) ZENECA, INC. ZANZIBAR ACQUISITION CORP. (Names of Filing Persons ? Offeror) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 98979G 105 (Cusip Number of C |
|
| November 10, 2015 |
Maria Groves, Associate Director, MedImmune (Cambridge, UK) Exhibit 99.2 Transcript of video regarding AstraZeneca plc?s strategy, as included on slide 26 in the presentation attached as Exhibit 99.1 Maria Groves, Associate Director, MedImmune (Cambridge, UK): At AstraZeneca, every day starts with this challenge: to push the boundaries of science to deliver life-changing medicines. This means making choices based on what the science is telling us?to be cur |
|
| November 10, 2015 |
AstraZeneca What Science Can Do Pascal Soriot Chief Executive Officer, AstraZeneca November 2015 EX-99.1 2 dp61117ex9901.htm EXHIBIT 99.1 Exhibit 99.1 AstraZeneca What Science Can Do Pascal Soriot Chief Executive Officer, AstraZeneca November 2015 This document contains certain forward - looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other fin |
|
| November 9, 2015 |
ZS Pharma FORM 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 6, 2015 |
Exhibit 99.1 News Release AstraZeneca STRENGTHENs CARDIOVASCULAR AND METABOLIC DISEASE PORTFOLIO with ACQUIsition of ZS PHArMA AstraZeneca to acquire ZS Pharma for $90 per share Acquisition includes potential best-in-class hyperkalaemia treatment currently under US FDA regulatory review Acquisition expected to contribute Product Sales from 2016 and benefit AstraZeneca?s return to growth strategy 0 |
|
| November 6, 2015 |
Subject: Message from Pascal Soriot, CEO AstraZeneca Exhibit 99.2 Subject: Message from Pascal Soriot, CEO AstraZeneca Dear all, Following today’s announcement, I wanted to share why I am so excited by the agreement that I hope will see ZS Pharma soon join AstraZeneca. Cardiovascular and metabolic disease is one of AstraZeneca’s main therapy areas and ZS Pharma will have an extremely important role to play in working with us to achieve our core purp |
|
| November 6, 2015 |
EX-99.1 Exhibit 99.1 News Release ASTRAZENECA STRENGTHENS CARDIOVASCULAR AND METABOLIC DISEASE PORTFOLIO WITH ACQUISITION OF ZS PHARMA AstraZeneca to acquire ZS Pharma for $90 per share Acquisition includes potential best-in-class hyperkalaemia treatment currently under US FDA regulatory review Acquisition expected to contribute Product Sales from 2016 and benefit AstraZeneca?s return to growth st |
|
| November 6, 2015 |
PROJECT ZANZIBAR KEY MESSAGES AND Q&A Exhibit 99.4 Q&A Project Zanzibar FINAL: 6 November 2015 PROJECT ZANZIBAR KEY MESSAGES AND Q&A 6 November 2015 Key messages • AstraZeneca has entered into an agreement to acquire ZS Pharma for $90 per share. • This acquisition strengthens our focus in Cardiovascular & Metabolic Disease by adding to our portfolio ZS-9, a potential best-in-class treatment for hyperkalaemia. It also leverages roxadus |
|
| November 6, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 ZS Pharma, Inc. (Name of Subject Company) ZENECA, INC. ZANZIBAR ACQUISITION CORP. (Names of Filing Persons ? Offeror) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 98979G 105 (Cusip Number of C |
|
| November 6, 2015 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 5, 2015 ZS Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36489 26-3305698 (State or Other Jurisdiction of Incorporation or Organization |
|
| November 6, 2015 |
EX-2.1 Exhibit 2.1 EXECUTION COPY AGREEMENT AND PLAN OF MERGER AMONG ZENECA, INC., ZANZIBAR ACQUISITION CORP. AND ZS PHARMA, INC. Dated as of November 5, 2015 TABLE OF CONTENTS Page ARTICLE I THE OFFER 2 Section 1.01 The Offer 2 Section 1.02 Company Action 4 ARTICLE II THE MERGER 5 Section 2.01 The Merger 5 Section 2.02 Consummation of the Merger 5 Section 2.03 Effects of the Merger 6 Section 2.04 |
|
| November 6, 2015 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 6, 2015 ZS Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36489 26-3305698 (State or Other Jurisdiction of Incorporation or Organization |
|
| November 6, 2015 |
A cquisition of ZS Pharma Conference call 6 November 2015 Exhibit 99.3 A cquisition of ZS Pharma Conference call 6 November 2015 This document contains certain forward - looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures . Although we believe our expectations are based on rea |
|
| November 6, 2015 |
Exhibit 99.1 From: Robert Alexander Sent: Friday, November 06, 2015 11:47 AM To: ZS Employees Subject: Message from Pascal Soriot Hi Everybody: I just got this email from Pascal and he asked that I forward it on to all of you. Have a great weekend! Robert Subject: Message from Pascal Soriot, CEO AstraZeneca Dear all, Following todays announcement, I wanted to share why I am so excited by the agre |
|
| September 10, 2015 |
Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 10, 2015 (September 10, 2015) ZS Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36489 26-3305698 (State or Other Jurisdiction of I |
|
| September 10, 2015 |
EX-99.1 Exhibit 99.1 ZS Pharma Corporate Statement SAN MATEO, Calif., September 10, 2015 (GLOBE NEWSWIRE) ? ZS Pharma, Inc. (Nasdaq:ZSPH), today confirmed that it has participated in preliminary discussions with Actelion Ltd. (OTC: ALIOF) regarding a potential strategic transaction. ZS Pharma regularly and routinely explores opportunities with various strategic partners and will continue to do so. |
|
| August 21, 2015 |
144 1 d39152d144.htm FORM 144 OMB APPROVAL OMB Number: 3235-0101 Expires: May 31, 2017 Estimated average burden hours per response 1.00 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933 SEC USE ONLY DOCUMENT SEQUENCE NO. CUSIP NUMBER WORK LOCATION ATTENTION: Transmit for filin |
|
| August 6, 2015 |
WAIVER AND FOURTH AMENDMENT TO CREDIT AND SECURITY AGREEMENT Exhibit 10.1 WAIVER AND FOURTH AMENDMENT TO CREDIT AND SECURITY AGREEMENT THIS WAIVER AND FOURTH AMENDMENT TO CREDIT AND SECURITY AGREEMENT (this ?Agreement?) is dated as of July 15, 2015, by and among ZS PHARMA, INC., a Delaware corporation (?Borrower?), MIDCAP FUNDING III TRUST, a Delaware statutory trust in its capacity as agent (?Agent?) for the lenders under the Credit Agreement (as defined b |
|
| August 6, 2015 |
ZS Pharma 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 6, 2015 (August 6, 2015) ZS Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36489 26-3305698 (State or Other Jurisdiction of Incorporation |
|
| August 6, 2015 |
ZS Pharma Reports Second Quarter 2015 Financial Results and Provides Corporate Update EX-99.1 Exhibit 99.1 ZS Pharma Reports Second Quarter 2015 Financial Results and Provides Corporate Update Redwood City, Calif. ? August 6, 2015 ? ZS Pharma, Inc. (Nasdaq: ZSPH), today reported its financial results for the second quarter ended June 30, 2015, and provided an overview of recent accomplishments. Recent Highlights ? Announced the submission of a New Drug Application (NDA) for ZS-9 (s |
|
| August 6, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| July 29, 2015 |
ZS Pharma Announces FDA Acceptance of ZS-9 New Drug Application - PDUFA date May 26, 2016 - EX-99.1 Exhibit 99.1 ZS Pharma Announces FDA Acceptance of ZS-9 New Drug Application - PDUFA date May 26, 2016 - Redwood City, Calif. ? July 29, 2015 ? ZS Pharma, Inc. (Nasdaq: ZSPH), today announced that its New Drug Application (NDA) for ZS-9 (sodium zirconium cyclosilicate) for the treatment of hyperkalemia, has been accepted for filing by the United States Food and Drug Administration (FDA). W |
|
| July 29, 2015 |
Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 29, 2015 (July 29, 2015) ZS Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36489 26-3305698 (State or Other Jurisdiction of Incorporati |
|
| July 21, 2015 |
S-8 1 d18721ds8.htm S-8 As filed with the Securities and Exchange Commission on July 21, 2015 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ZS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 26-3305698 (State or other jurisdiction of incorporation or organiz |
|
| June 23, 2015 |
ZS PHARMA, INC. 2015 EMPLOYEE STOCK PURCHASE PLAN EX-10.1 Exhibit 10.1 ZS PHARMA, INC. 2015 EMPLOYEE STOCK PURCHASE PLAN 1. Purpose. The purpose of the Plan is to provide employees of the Company and its Designated Companies with an opportunity to purchase Common Stock through accumulated Contributions. The Company intends for the Plan to have two components: a Code Section 423 Component (?423 Component?) and a non-Code Section 423 Component (?No |
|
| June 23, 2015 |
ZS Pharma FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 23, 2015 (June 18, 2015) ZS Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36489 26-3305698 (State or Other Jurisdiction of Incorporati |
|
| June 23, 2015 |
ZS PHARMA, INC. 2014 INCENTIVE PLAN NON-EMPLOYEE DIRECTOR RESTRICTED STOCK UNIT AWARD GRANT NOTICE EX-10.3 Exhibit 10.3 ZS PHARMA, INC. 2014 INCENTIVE PLAN NON-EMPLOYEE DIRECTOR RESTRICTED STOCK UNIT AWARD GRANT NOTICE ZS Pharma, Inc., a Delaware corporation, (the ?Company?), pursuant to the ZS Pharma, Inc. 2014 Incentive Plan, as amended from time to time (the ?Plan?), hereby grants to the holder listed below (?Participant?), an award of restricted stock units (?RSUs?). Each RSU represents the |
|
| June 23, 2015 |
ZS PHARMA, INC. 2014 INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE EX-10.2 Exhibit 10.2 ZS PHARMA, INC. 2014 INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE ZS Pharma, Inc., a Delaware corporation, (the ?Company?), pursuant to the ZS Pharma, Inc. 2014 Incentive Plan, as amended from time to time (the ?Plan?), hereby grants to the holder listed below (?Participant?), an award of restricted stock units (?RSUs?). Each RSU represents the right to receive one |
|
| June 16, 2015 |
ZS Pharma Names Jeffrey Farrow as Chief Financial Officer EX-99.1 Exhibit 99.1 ZS Pharma Names Jeffrey Farrow as Chief Financial Officer Redwood City, Calif. ? June 16, 2015 ? ZS Pharma, Inc. (Nasdaq: ZSPH), a biopharmaceutical company focused on the development and commercialization of highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic disorders, today announced the appointment of Jeffrey Farrow as chief financial o |
|
| June 16, 2015 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 15, 2015 ZS Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36489 26-3305698 (State or Other Jurisdiction of Incorporation or Organization) ( |
|
| June 9, 2015 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 2) (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a) ZS Pharma, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 98979G 105 (CUSIP Number) Larry Randall Alta Partners One Embarcadero Cen |
|
| June 3, 2015 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 1) (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a) ZS Pharma, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 98979G 105 (CUSIP Number) Larry Randall Alta Partners One Embarcadero Cen |
|
| May 28, 2015 |
ZS Pharma Announces Participation at Upcoming Investor Conferences EX-99.1 Exhibit 99.1 ZS Pharma Announces Participation at Upcoming Investor Conferences Redwood City, Calif. ? May 28, 2015 ? ZS Pharma, Inc. (Nasdaq: ZSPH), a biopharmaceutical company focused on the development and commercialization of highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic disorders, today announced that management will present at the following |
|
| May 28, 2015 |
ZS Pharma FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 28, 2015 (May 28, 2015) ZS Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36489 26-3305698 (State or Other Jurisdiction of Incorporation |
|
| May 26, 2015 |
EX-99.1 Exhibit 99.1 ZS Pharma Submits New Drug Application to U.S. Food and Drug Administration for ZS-9 for the Treatment of Hyperkalemia Redwood City, Calif. ? May 26, 2015 ? ZS Pharma, Inc. (Nasdaq: ZSPH), a biopharmaceutical company focused on the development and commercialization of highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic disorders, today anno |
|
| May 26, 2015 |
ZS Pharma FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 26, 2015 (May 26, 2015) ZS Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36489 26-3305698 (State or Other Jurisdiction of Incorporation |
|
| May 12, 2015 |
ZS Pharma Announces Multiple ZS-9 Data Presentations at Upcoming Medical Meetings EX-99.1 Exhibit 99.1 ZS Pharma Announces Multiple ZS-9 Data Presentations at Upcoming Medical Meetings Redwood City, Calif. ? May 12, 2015 ? ZS Pharma, Inc. (Nasdaq: ZSPH), a biopharmaceutical company focused on the development and commercialization of highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic disorders, today announced that data from the Phase 3 tria |
|
| May 12, 2015 |
ZS Pharma FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 12, 2015 (May 12, 2015) ZS Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36489 26-3305698 (State or Other Jurisdiction of Incorporation |
|
| May 11, 2015 |
PARK PLACE AT BAY MEADOWS OFFICE LEASE EX-10.3 Exhibit 10.3 PARK PLACE AT BAY MEADOWS OFFICE LEASE This Office Lease (the “Lease”), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the “Summary”), below, is made by and between PARK PLACE REALTY HOLDING COMPANY, INC., a Delaware corporation (“Landlord”), and ZS PHARMA, INC., a Delaware corporation (“Tenant”). SUMMARY OF BASIC LEASE INFORMATION TERMS |
|
| May 11, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| May 11, 2015 |
THIRD AMENDMENT TO CREDIT AND SECURITY AGREEMENT Exhibit 10.2 THIRD AMENDMENT TO CREDIT AND SECURITY AGREEMENT THIS THIRD AMENDMENT TO CREDIT AND SECURITY AGREEMENT (this ?Agreement?) is dated as of April 30, 2015, by and among ZS PHARMA, INC., a Delaware corporation (?Borrower?), MIDCAP FUNDING III TRUST, a Delaware statutory trust in its capacity as agent (?Agent?) for the lenders under the Credit Agreement (as defined below) (?Lenders?), and |
|
| May 11, 2015 |
ZS Pharma FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 11, 2015 (May 11, 2015) ZS Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36489 26-3305698 (State or Other Jurisdiction of Incorporation |
|
| May 11, 2015 |
AMENDMENT EMPLOYMENT AGREEMENT Exhibit 10.4 AMENDMENT TO EMPLOYMENT AGREEMENT This Amendment (?Amendment?) to the existing Employment Agreement, by and between ZS Pharma, Inc. (?ZS Pharma?) and the undersigned employee of ZS Pharma (?Employee?), originally entered into on the date indicated below Employee?s signature, (the ?Employment Agreement?) and as amended on March 21, 2014, is hereby made and entered into by ZS Pharma and |
|
| May 11, 2015 |
ZS Pharma Reports First Quarter 2015 Financial Results and Provides ZS-9 Program Update Exhibit 99.1 ZS Pharma Reports First Quarter 2015 Financial Results and Provides ZS-9 Program Update Redwood City, Calif. May 11, 2015 ZS Pharma, Inc. (Nasdaq: ZSPH), a biopharmaceutical company focused on the development and commercialization of highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic disorders, today provided a program update on ZS-9 (sodium z |
|
| May 11, 2015 |
ZS PHARMA, INC. EMPLOYMENT AGREEMENT Exhibit 10.5 ZS PHARMA, INC. EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) is entered into between ZS Pharma, Inc., a Delaware corporation (?ZS Pharma?), and Mark Asbury (?Employee?). In consideration of the premises and the following mutual terms and conditions, ZS Pharma and Employee agree as follows: 1. Employment At Will. Employee is employed by ZS Pharma as an employee at |
|
| May 8, 2015 |
*** Exercise Your Right to Vote *** Important Notice Regarding the Availability of Proxy Materials for the Shareholder Meeting to Be Held on June 18, 2015 Meeting Information ZS PHARMA INC. |
|
| May 8, 2015 |
ZS Pharma DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of |
|
| May 6, 2015 |
ZS Pharma 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 6, 2015 (May 6, 2015) ZS Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36489 26-3305698 (State or Other Jurisdiction of Incorporation or Org |
|
| May 6, 2015 |
ZS Pharma to Present at Bank of America Merrill Lynch 2015 Health Care Conference EX-99.1 Exhibit 99.1 ZS Pharma to Present at Bank of America Merrill Lynch 2015 Health Care Conference Redwood City, Calif. ? May 6, 2015 ? ZS Pharma, Inc. (Nasdaq: ZSPH), a biopharmaceutical company focused on the development and commercialization of highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic disorders, today announced that management will present at |
|
| May 5, 2015 |
ZS Pharma Appoints Kimberly Popovits to Board of Directors EX-99.1 Exhibit 99.1 ZS Pharma Appoints Kimberly Popovits to Board of Directors REDWOOD CITY, Calif. ? May 5, 2015 - ZS Pharma (NASDAQ: ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced that Kimberly J. Popovits, Chairman of the Board, Chief Executive Officer and President of Genomic Health, has been appointed |
|
| May 5, 2015 |
FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 5, 2015 (May 1, 2015) ZS Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36489 26-3305698 (State or Other Jurisdiction of Incorporation o |
|
| April 15, 2015 |
ZS Pharma FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 15, 2015 (April 15, 2015) ZS Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36489 26-3305698 (State or Other Jurisdiction of Incorpora |
|
| April 15, 2015 |
EX-99.1 Exhibit 99.1 ZS Pharma Announces Publications in Peer-Reviewed Medical Journals ? NEJM letter to the Editor highlights rapid efficacy in patients with severe hyperkalemia ? ? Phase 2 first-in-man study of ZS-9 published in Kidney International ? Redwood City, Calif. ? April 15, 2015 ? ZS Pharma (Nasdaq: ZSPH), a biopharmaceutical company focused on the development and commercialization of |
|
| March 25, 2015 |
ZS Pharma Announces Upsizing and Pricing of $186 Million Public Offering of Common Stock EX-99.1 Exhibit 99.1 ZS Pharma Announces Upsizing and Pricing of $186 Million Public Offering of Common Stock Redwood City, Calif. ? March 24, 2015 ? ZS Pharma, Inc. (Nasdaq: ZSPH), a biopharmaceutical company focused on the development and commercialization of highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic disorders, today announced the upsizing and prici |
|
| March 25, 2015 |
424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-202745 4,015,939 Shares Common Stock ZS Pharma, Inc. is selling 4,015,939 shares of common stock in this offering. Our common stock is listed on The Nasdaq Global Market under the symbol ?ZSPH?. The last reported sale price of our common stock on The Nasdaq Global Market on March 24, 2015 was $46.59 per share. We are an |
|
| March 25, 2015 |
ZS Pharma FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 24, 2015 (March 24, 2015) ZS Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36489 26-3305698 (State or Other Jurisdiction of Incorpora |
|
| March 24, 2015 |
As filed with the Securities and Exchange Commission on March 24, 2015. Registration No. 333-202745 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ZS PHARMA, INC. (Exact name of Registrant as specified in its charter) Delaware 2834 26-3305698 (State or other jurisdiction of incorporation or |
|
| March 24, 2015 |
S-1MEF As filed with the Securities and Exchange Commission on March 24, 2015 No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ZS PHARMA, INC. (Exact name of Registrant as specified in its charter) Delaware 2384 26-3305698 (State or other jurisdiction of incorporation or organization) (Primary Standard |
|
| March 24, 2015 |
EX-1.1 Exhibit 1.1 J.P. MORGAN SECURITIES LLC UNDERWRITING AGREEMENT ZS PHARMA, INC. [ ] Shares of Common Stock Underwriting Agreement [March , 2015] J.P. Morgan Securities LLC Credit Suisse Securities (USA) LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 and Credit Suisse Securities (USA) LLC |
|
| March 23, 2015 |
ZS Pharma Announces Proposed Public Offering of Common Stock EX-99.1 Exhibit 99.1 ZS Pharma Announces Proposed Public Offering of Common Stock Redwood City, Calif. ? March 23, 2015 ? ZS Pharma, Inc. (Nasdaq: ZSPH), a biopharmaceutical company focused on the development and commercialization of highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic disorders, today announced that it intends to offer and sell, subject to mark |
|
| March 23, 2015 |
ZS Pharma FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 23, 2015 (March 23, 2015) ZS Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36489 26-3305698 (State or Other Jurisdiction of Incorpora |
|
| March 23, 2015 |
As filed with the Securities and Exchange Commission on March 23, 2015. Table of Contents As filed with the Securities and Exchange Commission on March 23, 2015. |
|
| March 19, 2015 |
EX-99.1 Exhibit 99.1 ZS Pharma to Present Data from Phase 3 Trials of ZS-9 in Presentations at the National Kidney Foundation 2015 Spring Clinical Meetings Redwood City, Calif. ? March 19, 2015 ? ZS Pharma, Inc. (Nasdaq: ZSPH), a biopharmaceutical company focused on the development and commercialization of highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic dis |
|
| March 19, 2015 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 19, 2015 (March 19, 2015) ZS Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36489 26-3305698 (State or Other Jurisdiction of Incorporation or O |
|
| March 13, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2014. or ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-36489 ZS PHAR |
|
| March 13, 2015 |
As filed with the Securities and Exchange Commission on March 13, 2015. Table of Contents As filed with the Securities and Exchange Commission on March 13, 2015. |
|
| March 13, 2015 |
ZS Pharma FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 13, 2015 (March 13, 2015) ZS Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36489 26-3305698 (State or Other Jurisdiction of Incorpora |
|
| March 13, 2015 |
Exhibit 10.17 Standard Form Office Lease Made and entered into at Redwood City, California between Harvard Investment Company (?Lessor?) and ZS Pharma, Inc. (?Lessee?). 1. Premises. (a) In consideration of the rent herein provided and the terms and conditions hereof, Lessor hereby leases to Lessee those certain premises, more particularly described in Exhibit ?A? attached hereto, situated in the P |
|
| March 13, 2015 |
EX-99.1 Exhibit 99.1 ZS Pharma Reports Fourth Quarter and Year-End 2014 Financial Results and Provides ZS-9 Program Update Redwood City, Calif. ? March 13, 2015 ? ZS Pharma, Inc. (Nasdaq: ZSPH), a biopharmaceutical company focused on the development and commercialization of highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic disorders, today provided a program |
|
| March 13, 2015 |
Code of Business Conduct and Ethics ZS PHARMA, INC. CODE OF BUSINESS CONDUCT AND ETHICS Exhibit 14 Code of Business Conduct and Ethics ZS PHARMA, INC. CODE OF BUSINESS CONDUCT AND ETHICS Conducting the business affairs of ZS Pharma, Inc. (the ?Company?) in accordance with the highest ethical standards and in compliance with legal requirements aligns directly with our goals of being value-driven and transparent. A reputation for being value-driven, transparent and honest builds the bo |
|
| March 13, 2015 |
EX-10.17 Exhibit 10.17 Standard Form Office Lease Made and entered into at Redwood City, California between Harvard Investment Company (“Lessor”) and ZS Pharma, Inc. (“Lessee”). 1. Premises. (a) In consideration of the rent herein provided and the terms and conditions hereof, Lessor hereby leases to Lessee those certain premises, more particularly described in Exhibit “A” attached hereto, situated |
|
| February 19, 2015 |
Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 19, 2015 (February 19, 2015) ZS Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36489 26-3305698 (State or Other Jurisdiction of Inc |
|
| February 19, 2015 |
EX-99.1 Exhibit 99.1 ZS Pharma Hires Key Medical Affairs and Commercial Executives — As ZS-9 nears NDA and MAA submissions, ZS Pharma adds key members to its Medical Affairs and Commercial leadership team – REDWOOD CITY, Calif. – February 19, 2015 - ZS Pharma (NASDAQ: ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today ann |
|
| February 13, 2015 |
ZSPH / ZS Pharma, Inc. / DEVON PARK BIOVENTURES LP - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ZS PHARMA, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 98979G105 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 12, 2015 |
ZSPH / ZS Pharma, Inc. / 3x5 Special Opportunity Fund, L.p. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ZS Pharma, Inc. (ZSPH) (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 98979G105 (CUSIP Number) December 31, 2014 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| February 10, 2015 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 10, 2015 (February 4, 2015) ZS Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36489 26-3305698 (State or Other Jurisdiction of Inco |
|
| February 10, 2015 |
EX-99.1 Exhibit 99.1 ZS Pharma Appoints Martin Babler to Board of Directors — As ZS-9 nears NDA and MAA submission, Company taps industry veteran to optimize commercial potential – COPPELL, Texas – February 10, 2015 - ZS Pharma (NASDAQ: ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced that Martin Babler, Chief |
|
| January 6, 2015 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 6, 2015 (January 6, 2015) ZS Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36489 26-3305698 (State or Other Jurisdiction of Incorporatio |
|
| January 6, 2015 |
ZS Pharma to Present at J.P. Morgan Healthcare Conference EX-99.1 Exhibit 99.1 ZS Pharma to Present at J.P. Morgan Healthcare Conference COPPELL, Texas - January 6, 2015 - ZS Pharma (NASDAQ: ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced that management will present at the J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco, Calif., o |
|
| November 21, 2014 |
EX-99.1 Exhibit 99.1 ZS Pharma Announces Publication of Results from Phase 3 Study of ZS-9 in Patients with Hyperkalemia in the New England Journal of Medicine - ZS-9 normalizes 98 percent of patients within 48 hours and a high proportion of patients who continued on ZS-9 maintained normokalemia - Coppell, Texas – November 21, 2014 – ZS Pharma (Nasdaq: ZSPH), a biopharmaceutical company developing |
|
| November 21, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 21, 2014 (November 21, 2014) ZS Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36489 26-3305698 (State or Other Jurisdiction of Incorpor |
|
| November 20, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 20, 2014 (November 19, 2014) ZS Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36489 26-3305698 (State or Other Jurisdiction of Incorpor |
|
| November 20, 2014 |
EX-99.1 Exhibit 99.1 ZS Pharma Hosts and Webcasts Investor Event - Webcast available on investor section of ZS Pharma website - COPPELL, Texas – November 19, 2014 - ZS Pharma (Nasdaq: ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced that it has made available on its website the presentation from the Company’s |
|
| November 17, 2014 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 17, 2014 (November 17, 2014) ZS Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36489 26-3305698 (State or Other Jurisdiction of Incorpor |
|
| November 17, 2014 |
EX-99.1 Exhibit 99.1 ZS Pharma Presents Positive Results from HARMONIZE (ZS004), a Second Phase 3 Clinical Trial of ZS-9 in Patients with Hyperkalemia, at the American Heart Association Scientific Meeting and Announces Simultaneous Publication of Results in JAMA Coppell, Texas – November 17, 2014 – ZS Pharma (Nasdaq: ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardio |
|
| November 10, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 10, 2014 |
ZS Pharma Reports Third Quarter 2014 Financial Results and Provides ZS-9 Program Update EX-99.1 Exhibit 99.1 ZS Pharma Reports Third Quarter 2014 Financial Results and Provides ZS-9 Program Update Coppell, Texas – November 10, 2014 – ZS Pharma, Inc. (Nasdaq: ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today reported financial results for the third quarter ended September 30, 2014 and provided a program upda |
|
| November 10, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 10, 2014 (November 10, 2014) ZS Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36489 26-3305698 (State or Other Jurisdiction of Incorpor |
|
| November 6, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 6, 2014 (November 6, 2014) ZS Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36489 26-3305698 (State or Other Jurisdiction of Incorporat |
|
| November 6, 2014 |
EX-99.1 Exhibit 99.1 ZS Pharma Announces Late Breaking Presentation of Phase 3 HARMONIZE (ZS004) Trial Results in Patients with Hyperkalemia at AHA Annual Meeting Additional ZS003 Phase 3 Presentations also Featured at American Heart Association (AHA) Annual Scientific Meeting Coppell, Texas – November 6, 2014 – ZS Pharma (Nasdaq: ZSPH), a biopharmaceutical company developing novel treatments for |
|
| October 30, 2014 |
EX-99.1 Exhibit 99.1 ZS Pharma Announces Multiple Presentations from ZS003, a Phase 3 Trial of ZS-9, at the American Society of Nephrology Annual Meeting Coppell, Texas – October 30, 2014 – ZS Pharma (Nasdaq: ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced that data from ZS003, a pivotal Phase 3 trial of ZS-9 |
|
| October 30, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 30, 2014 (October 30, 2014) ZS Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36489 26-3305698 (State or Other Jurisdiction of Incor |
|
| October 28, 2014 |
ZS Pharma to Present at the Credit Suisse Annual Healthcare Conference EX-99.1 Exhibit 99.1 ZS Pharma to Present at the Credit Suisse Annual Healthcare Conference COPPELL, Texas – October 28, 2014—ZS Pharma (Nasdaq: ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced that management will present at the Credit Suisse Annual Healthcare Conference at the Biltmore Hotel in Phoenix, Ariz |
|
| October 28, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 28, 2014 (October 28, 2014) ZS Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36489 26-3305698 (State or Other Jurisdiction of Incorporat |
|
| September 23, 2014 |
EX-99.1 Exhibit 99.1 ZS Pharma Announces Positive Top-Line Results from HARMONIZE (ZS004), a Second Phase 3 Clinical Trial of ZS-9 in Patients with Hyperkalemia ZS-9 meets primary endpoint at all three doses tested Coppell, Texas – September 23, 2014 – ZS Pharma (Nasdaq: ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today |
|
| September 23, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 23, 2014 (September 23, 2014) ZS Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36489 26-3305698 (State or Other Jurisdiction of Incorp |
|
| September 17, 2014 |
ZS Pharma to Present at the 21st Annual BioCentury NewsMakers Conference EX-99.1 Exhibit 99.1 ZS Pharma to Present at the 21st Annual BioCentury NewsMakers Conference COPPELL, Texas – September 17, 2014—ZS Pharma (Nasdaq: ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced that management will present at the 21st Annual BioCentury NewsMakers Conference at the Millennium Broadway Hotel |
|
| September 17, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 17, 2014 (September 17, 2014) ZS Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36489 26-3305698 (State or Other Jurisdiction of Incorp |
|
| September 16, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 15, 2014 (September 15, 2014) ZS Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36489 26-3305698 (State or Other Jurisdiction of Incorp |
|
| September 16, 2014 |
EX-99.1 Exhibit 99.1 ZS Pharma Presents New Data from ZS003 a Two Week Phase 3 Trial Demonstrating that ZS-9 Prevented Recurrence of Hyperkalemia in Heart Failure Patients on RAASi Data Featured as Oral Presentation During a Late-Breaking Clinical Trial Session at the Heart Failure Society of America (HFSA) 18th Annual Scientific Meeting Coppell, Texas – September 15, 2014 – ZS Pharma (Nasdaq: ZSP |
|
| September 11, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 11, 2014 (September 11, 2014) ZS Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36489 26-3305698 (State or Other Jurisdiction of Incorp |
|
| September 11, 2014 |
EX-99.1 Exhibit 99.1 ZS Pharma to Present Data from Phase 3 Trial of ZS-9 in Late-Breaking Session at Heart Failure Society of America 18th Annual Scientific Meeting Coppell, Texas – September 11, 2014 – ZS Pharma (Nasdaq: ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced that a secondary analysis of data from |
|
| August 26, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 26, 2014 (August 26, 2014) ZS Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36489 26-3305698 (State or Other Jurisdiction of Incorporatio |
|
| August 26, 2014 |
EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE ZS Pharma to Present Late-Breaking Abstract Data from Phase 3 Trial of ZS-9 in State of the Art and Featured Research Session Oral Presentation at European Society of Cardiology (ESC) Congress Coppell, Texas – August 26, 2014 – ZS Pharma (Nasdaq: ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic |
|
| August 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| August 14, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 14, 2014 (August 14, 2014) ZS Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36489 26-3305698 (State or Other Jurisdiction of Incorpo |
|
| August 14, 2014 |
ZS Pharma Announces Second Quarter 2014 Financial Results EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE ZS Pharma Announces Second Quarter 2014 Financial Results Coppell, Texas – August 14, 2014 – ZS Pharma, Inc. (Nasdaq: ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today reported financial results for the second quarter ended June 30, 2014. “Our first quarter reporting as a public |
|
| August 14, 2014 |
Exhibit 4.1 FOURTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT Amended and Restated as of June 23, 2014 TABLE OF CONTENTS Page 1. Definitions 1 2. Registration Rights 4 2.1 Demand Registration 4 2.2 Company Registration 5 2.3 Underwriting Requirements 6 2.4 Obligations of the Company 7 2.5 Furnish Information 9 2.6 Expenses of Registration 9 2.7 Delay of Registration 9 2.8 Indemnification 9 2 |
|
| July 17, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 17, 2014 (July 14, 2014) ZS Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36489 26-3305698 (State or Other Jurisdiction of Incorporati |
|
| July 17, 2014 |
EX-10.1 Exhibit 10.1 EXECUTION COPY CREDIT AND SECURITY AGREEMENT THIS CREDIT AND SECURITY AGREEMENT (this Agreement), dated as of July 14, 2014 (the Closing Date) by and among MIDCAP FINANCIAL SBIC, LP, a Delaware limited partnership (MidCap), as administrative agent (Agent), the Lenders listed on the Credit Facility Schedule attached hereto and otherwise party hereto from time to time (e |
|
| July 17, 2014 |
ZS Pharma Secures $20 Million in Debt Financing EX-99.1 Exhibit 99.1 ZS Pharma Secures $20 Million in Debt Financing Coppell, Texas – July 17, 2014 – ZS Pharma (Nasdaq: ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced that it has secured a debt facility of up to $20 million with MidCap Financial. The Company will use the funding to advance the clinical deve |
|
| July 14, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 14, 2014 (July 14, 2014) ZS Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36489 26-3305698 (State or Other Jurisdiction of Incorporati |
|
| July 14, 2014 |
EX-99.1 Exhibit 99.1 ZS Pharma Completes Patient Enrollment in ZS004, Its Second Phase 3 Study of ZS-9 in Patients with Hyperkalemia Company expects to announce top-line results late Q3 or early Q4 2014 Coppell, Texas – July 14, 2014 – ZS Pharma, a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, announced today that it has completed |
|
| July 8, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 d753115d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 8, 2014 (July 8, 2014) ZS Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36489 26-3305698 (State or Other Jurisdiction |
|
| July 8, 2014 |
EX-99.1 Exhibit 99.1 ZS Pharma Announces Allowance of Two U.S. Patent Applications for ZS-9 Applications cover composition of matter and methods of treating hyperkalemia and carry a patent term to at least 2032 Coppell, Texas – July 8, 2014 – ZS Pharma, a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, announced today that it has rec |
|
| July 3, 2014 |
ZS PHARMA, INC. FORM OF NONQUALIFIED STOCK OPTION GRANT NOTICE (2014 INCENTIVE PLAN) EX-4.7 Exhibit 4.7 ZS PHARMA, INC. FORM OF NONQUALIFIED STOCK OPTION GRANT NOTICE (2014 INCENTIVE PLAN) ZS Pharma, Inc. (the “Company”), pursuant to its 2014 Incentive Plan, as may be amended from time to time (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and condition |
|
| July 3, 2014 |
ZSPH / ZS Pharma, Inc. / Alta Partners VIII, L.P. - SCHEDULE 13D 7-3-14 Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a) ZS Pharma, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 98979G 105 (CUSIP Number) Larry Randall Alta Partners One Embarcadero Center, Suite 3700 Sa |
|
| July 3, 2014 |
ZSPH / ZS Pharma, Inc. S-8 - - FORM S-8 Form S-8 As filed with the Securities and Exchange Commission on July 3, 2014 Registration No. |
|
| July 3, 2014 |
ZS PHARMA, INC. FORM OF INCENTIVE STOCK OPTION GRANT NOTICE (2014 INCENTIVE PLAN) EX-4.6 Exhibit 4.6 ZS PHARMA, INC. FORM OF INCENTIVE STOCK OPTION GRANT NOTICE (2014 INCENTIVE PLAN) ZS Pharma, Inc. (the “Company”), pursuant to its 2014 Incentive Plan, as may be amended from time to time (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions a |
|
| June 26, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 d746440d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 26, 2014 (June 26, 2014) ZS Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36489 26-3305698 (State or Other Jurisd |
|
| June 26, 2014 |
EX-99.1 Exhibit 99.1 ZS Pharma Announces Start of Enrollment of Phase 3 Long-Term Maintenance Study of ZS-9 in Patients with Hyperkalemia —Open-Label Safety Study Evaluating Long-Term Safety and Efficacy of Oral Investigational Hyperkalemia Treatment— Coppell, Texas – June 26, 2014 – ZS Pharma, a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic |
|
| June 24, 2014 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 24, 2014 (June 23, 2014) ZS Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36489 26-3305698 (State or Other Jurisdiction of Incorporation or |
|
| June 23, 2014 |
SEVENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION ZS PHARMA, INC. EX-3.1 3 d744844dex31.htm EX-3.1 Exhibit 3.1 SEVENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ZS PHARMA, INC. The present name of the corporation is ZS Pharma, Inc. (the “Corporation”). The Corporation was incorporated under the name “ZS Pharma, Inc.” by the filing of its original certificate of incorporation (the “Original Certificate of Incorporation”) with the Secretary of State of |
|
| June 23, 2014 |
AMENDED AND RESTATED BYLAWS ZS PHARMA, INC. (hereinafter called the “Corporation”) ARTICLE I EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS of ZS PHARMA, INC. (hereinafter called the “Corporation”) ARTICLE I OFFICES 1.1 Registered Office. The registered office of the Corporation required by the General Corporation Law of the State of Delaware or any successor statute (as amended from time to time, the “DGCL”) to be maintained in the State of Delaware shall be the registered office named i |
|
| June 23, 2014 |
EX-1.1 Exhibit 1.1 EXECUTION VERSION J.P. MORGAN SECURITIES LLC FORM OF UNDERWRITING AGREEMENT ZS PHARMA, INC. 5,944,444 Shares of Common Stock Underwriting Agreement June 17, 2014 J.P. Morgan Securities LLC Credit Suisse Securities (USA) LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 and Cre |
|
| June 23, 2014 |
8-K 1 d744844d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 23, 2014 (June 17, 2014) ZS Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36489 26-3305698 (State or Other Jurisd |
|
| June 23, 2014 |
EX-10.6 5 d744844dex106.htm EX-10.6 Exhibit 10.6 ZS PHARMA, INC. 2014 INCENTIVE PLAN ZS PHARMA, INC. 2014 INCENTIVE PLAN Table of Contents Page 1. Plan 1 2. Objectives 1 3. Definitions 1 4. Eligibility 5 5. Common Stock Available for Awards 5 6. Administration 7 7. Delegation of Authority 8 8. Employee Awards 8 9. Consultant and Director Awards 12 10. Award Payment; Dividends and Dividend Equivale |
|
| June 23, 2014 |
ZS Pharma, Inc. Announces Pricing of Initial Public Offering EX-99.1 Exhibit 99.1 ZS Pharma, Inc. Announces Pricing of Initial Public Offering Coppell, Texas – June 17, 2014 – ZS Pharma, Inc., a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced the pricing of its initial public offering of 5,944,444 shares of its common stock at a price to the public of $18.00 per share. The shar |
|
| June 18, 2014 |
424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-195961 5,944,444 shares Common Stock This is an initial public offering of common stock by ZS Pharma, Inc. We are selling 5,944,444 shares of common stock. Prior to this offering, there has been no public market for our common stock. Our common stock has been approved for listing on The NASDAQ Global Market under the sym |
|
| June 17, 2014 |
S-1MEF As filed with the Securities and Exchange Commission on June 17, 2014. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ZS PHARMA, INC. (Exact name of Registrant as specified in its charter) Delaware 2834 26-3305698 (State or other jurisdiction of incorporation or organization) (Pri |
|
| June 13, 2014 |
CORRESP 1 filename1.htm ZS Pharma, Inc. 508 Wrangler Drive, Suite 100 Coppell, Texas 75019 June 13, 2014 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Jeffrey P. Riedler, Assistant Director Scott Wuenschell Joel Parker Christina De Rosa Dan Greenspan Re: ZS Pharma, Inc. Registration Statement on |
|
| June 13, 2014 |
J.P. Morgan Securities LLC 383 Madison Avenue New York, NY 10179 Credit Suisse Securities (USA) LLC Eleven Madison Avenue New York, NY 10010 June 13, 2014 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Jeffrey P. Riedler, Assistant Director Scott Wuenschell Joel Parker Christina De Rosa Dan Greenspan Re: ZS Pharma, Inc. |
|
| June 12, 2014 |
Amendment No. 3 to Form S-1 Table of Contents As filed with the Securities and Exchange Commission on June 12, 2014. Registration No. 333-195961 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 3 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ZS PHARMA, INC. (Exact name of Registrant as specified in its charter) Delaware 2834 26-3305698 (St |
|
| June 12, 2014 |
FORM OF SEVENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION ZS PHARMA, INC. EX-3.1 Exhibit 3.1 FORM OF SEVENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ZS PHARMA, INC. The present name of the corporation is ZS Pharma, Inc. (the “Corporation”). The Corporation was incorporated under the name “ZS Pharma, Inc.” by the filing of its original certificate of incorporation (the “Original Certificate of Incorporation”) with the Secretary of State of the State of Delaw |
|
| June 11, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ZS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 26-3305698 (State of incorporation or organization) (I.R.S. Employer Identification No.) 508 Wrangler Drive, Suite 10 |
|
| June 6, 2014 |
CORRESP June 6, 2014 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Attention: Jeffrey P. Riedler Re: ZS Pharma, Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed May 30, 2014 File No. 333-195961 Ladies and Gentlemen: Set forth below is the response of ZS Pharma, Inc. (the “Company”) to the comment contained in the le |
|
| June 6, 2014 |
Consent of Director Nominee ZS Pharma, Inc. 508 Wrangler Drive Suite 100 Coppell, Texas 75019 EX-99.2 Exhibit 99.2 Consent of Director Nominee ZS Pharma, Inc. 508 Wrangler Drive Suite 100 Coppell, Texas 75019 Pursuant to Rule 438 of Regulation C promulgated under the Securities Act of 1933, as amended (the “Securities Act”), in connection with the Registration Statement on Form S-1 (the “Registration Statement”) of ZS Pharma, Inc. (the “Company”), the undersigned hereby consents to being n |
|
| June 6, 2014 |
Amendment No. 2 to Form S-1 Table of Contents As filed with the Securities and Exchange Commission on June 6, 2014. Registration No. 333-195961 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ZS PHARMA, INC. (Exact name of Registrant as specified in its charter) Delaware 2834 26-3305698 (Sta |
|
| June 4, 2014 |
CORRESP 98 SAN JACINTO BLVD. SUITE 1500 AUSTIN, TEXAS 78701-4078 TEL +1 512.322.2500 FAX +1 512.322.2501 BakerBotts.com ABU DHABI AUSTIN BEIJING BRUSSELS DALLAS DUBAI HONG KONG HOUSTON LONDON MOSCOW NEW YORK PALO ALTO RIO DE JANEIRO RIYADH WASHINGTON June 3, 2014 Mollie Duckworth TEL: 5123222551 FAX: 5123228362 [email protected] U.S. Securities and Exchange Commission Division of Cor |
|
| June 4, 2014 |
begin 644 filename2.pdf M)5!$1BTQ+C8-)>+CS],-"C$@,"!O8FH*/#PO365T861A=&$@,3$P(#`@4B]0 M86=E7!E+T-A=&%L;V<^/@IE;F1O8FH*,B`P(&]B:@H\/"]- M961I84)O>%LP+C`@,"XP(#8Q,BXP(#7!E+U!A M9V5S+TMI9'-;-C`@,"!2(#@Q(#`@4B`U.2`P(%)=/CX*96YD;V)J"C,@,"!O M8FH*/#PO0W)E871I;VY$871E*$0Z,C`Q-#`V,#0P-#$R-#1:*2]0%LP(#`@ M-C$R(#<&4O4&%G93X^"F5N9&]B:@HV M(#`@;V)J"CP\+T9O;G0\/"]&,R`Q."`P(%(O1C0@,3,@,"!2+T8U(#@@,"!2 M/CXO4')O |
|
| May 30, 2014 |
EX-10.1 Exhibit 10.1 FORM OF FOURTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT Amended and Restated as of [ ], 2014 TABLE OF CONTENTS Page 1. Definitions 1 2. Registration Rights 4 2.1 Demand Registration. 4 2.2 Company Registration 6 2.3 Underwriting Requirements. 6 2.4 Obligations of the Company 7 2.5 Furnish Information 9 2.6 Expenses of Registration 9 2.7 Delay of Registration 9 2.8 Inde |
|
| May 30, 2014 |
EX-10.6 Exhibit 10.6 FORM OF ZS PHARMA, INC. 2014 INCENTIVE PLAN ZS PHARMA, INC. 2014 INCENTIVE PLAN Table of Contents Page 1. Plan 1 2. Objectives 1 3. Definitions 1 4. Eligibility 5 5. Common Stock Available for Awards 5 6. Administration 7 7. Delegation of Authority 8 8. Employee Awards 8 9. Consultant and Director Awards 12 10. Award Payment; Dividends and Dividend Equivalents 13 11. Option Ex |
|
| May 30, 2014 |
Consent of Director Nominee ZS Pharma, Inc. 508 Wrangler Drive Suite 100 Coppell, Texas 75019 EX-99.1 Exhibit 99.1 Consent of Director Nominee ZS Pharma, Inc. 508 Wrangler Drive Suite 100 Coppell, Texas 75019 Pursuant to Rule 438 of Regulation C promulgated under the Securities Act of 1933, as amended (the “Securities Act”), in connection with the Registration Statement on Form S-1 (the “Registration Statement”) of ZS Pharma, Inc. (the “Company”), the undersigned hereby consents to being n |
|
| May 30, 2014 |
FORM OF AMENDED AND RESTATED BYLAWS ZS PHARMA, INC. (hereinafter called the “Corporation”) ARTICLE I EX-3.2 Exhibit 3.2 FORM OF AMENDED AND RESTATED BYLAWS of ZS PHARMA, INC. (hereinafter called the “Corporation”) ARTICLE I OFFICES 1.1 Registered Office. The registered office of the Corporation required by the General Corporation Law of the State of Delaware or any successor statute (as amended from time to time, the “DGCL”) to be maintained in the State of Delaware shall be the registered office |
|
| May 30, 2014 |
CORRESP Confidential Treatment Requested by ZS Pharma, Inc. Under 17 C.F.R. § 200.83 FOIA Confidential Treatment Request May 30, 2014 Via EDGAR and HAND DELIVERY U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attention: Jeffrey P. Riedler Re: ZS Pharma, Inc. Stock-Based Compensation Registration Statement on Form S-1 (File No. 333 |
|
| May 30, 2014 |
AMENDMENT #1 TO FORM S-1 Table of Contents As filed with the Securities and Exchange Commission on May 30, 2014. |
|
| May 30, 2014 |
EX-10.19 Exhibit 10.19 FORM OF AMENDMENT TO EMPLOYMENT AGREEMENT This Amendment (“Amendment”) to the existing Employment Agreement, by and between ZS Pharma, Inc. (“ZS Pharma”) and the undersigned employee of ZS Pharma (“Employee”), originally entered into on the date indicated below Employee’s signature, (the “Employment Agreement”), is hereby made and entered into by ZS Pharma and Employee effec |
|
| May 30, 2014 |
CORRESP May 30, 2014 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Attention: Jeffrey P. Riedler Re: ZS Pharma, Inc. Registration Statement on Form S-1 Filed May 15, 2014 File No. 333-195961 Ladies and Gentlemen: Set forth below is the response of ZS Pharma, Inc. (the “Company”) to the comment contained in the letter from the staff |
|
| May 30, 2014 |
FORM OF SEVENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION ZS PHARMA, INC. EX-3.1 Exhibit 3.1 FORM OF SEVENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ZS PHARMA, INC. The present name of the corporation is ZS Pharma, Inc. (the “Corporation”). The Corporation was incorporated under the name “ZS Pharma, Inc.” by the filing of its original certificate of incorporation (the “Original Certificate of Incorporation”) with the Secretary of State of the State of Delaw |
|
| May 15, 2014 |
10 RULES AND REGULATIONS For 873 Santa Cruz Avenue, Menlo Park, CA EX-10.15 Exhibit 10.15 INDUSTRIAL & COMMERCIAL REAL ESTATE PARTIES This Lease, executed in duplicate at Palo Alto, California, this 26 day of April, 2013, by and between Renault & Handley Oakmead Solar Joint Venture LP, a California limited partnership, and ZS Pharma, Inc., a Delaware corporation, hereinafter referred to respectively as “Lessor” and “Lessee”, without regard to number or gender. PR |
|
| May 15, 2014 |
ZS PHARMA, INC. FORM OF INDEMNIFICATION AGREEMENT EX-10.2 Exhibit 10.2 ZS PHARMA, INC. FORM OF INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “Agreement”) is dated as of , 20 , and is between ZS Pharma, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). RECITALS A. Indemnitee’s service to the Company substantially benefits the Company. B. Individuals are reluctant to serve as directors or officers of corporations or |
|
| May 15, 2014 |
ZS PHARMA, INC. FORM OF EMPLOYMENT AGREEMENT EX-10.9 Exhibit 10.9 ZS PHARMA, INC. FORM OF EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into between ZS Pharma, Inc., a Delaware corporation (“ZS Pharma”), and the undersigned employee (“Employee”). In consideration of the premises and the following mutual terms and conditions, ZS Pharma and Employee agree as follows: 1. Employment At Will. Employee is employed by |
|
| May 15, 2014 |
EX-1.1 Exhibit 1.1 J.P. MORGAN SECURITIES LLC FORM OF UNDERWRITING AGREEMENT ZS PHARMA, INC. [•] Shares of Common Stock Underwriting Agreement [•], 2014 J.P. Morgan Securities LLC Credit Suisse Securities (USA) LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 and Credit Suisse Securities (USA) |
|
| May 15, 2014 |
ZS PHARMA, INC. FOURTH AMENDED STOCK INCENTIVE PLAN EX-10.3 Exhibit 10.3 ZS PHARMA, INC. FOURTH AMENDED STOCK INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Fourth Amended Stock Incentive Plan (the “Plan”), dated February 28, 2014, are to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to Employees and Consultants, and to promote the success of the Company’s |
|
| May 15, 2014 |
Exhibit 10.14 PARK WEST COMMERCE CENTER LEASE BY AND BETWEEN PW COMMERCE CENTER LP, a Texas limited partnership, as Landlord AND ZS PHARMA, INC., a Delaware corporation, as Tenant Table of Contents 1. Basic Lease Terms 1 2. Delivery of Possession, Initial Improvements, Commencement 3 3. Lease Term; Early Occupancy 4 4. Rent Payment 4 5. Security Deposit 5 6. Use of the Premises; Hazardous Substanc |
|
| May 15, 2014 |
EX-10.18 Exhibit 10.18 June 29, 2012 ZS Pharma, Inc. 1120 South Freeway Fort Worth, TX 76104 Attention: Alvaro Guillem Chief Executive Officer Jeffrey Keyser Chief Operating Officer 1. This agreement (the “Agreement”) confirms the engagement (the “Engagement”) of Salem Partners LLC (“Salem Partners”) on an exclusive basis as financial advisor to ZS Pharma, Inc. (the “Company”) in connection with a |
|
| May 15, 2014 |
EX-10.13 Exhibit 10.13 LEASE AGREEMENT THIS LEASE AGREEMENT (“Lease”) made as of this 1st day of August, 2013 between the University of North Texas Health Science Center at Fort Worth, a state institution of higher education, hereinafter referred to as “Landlord”, and ZS Pharma, Inc. having a business address at 508 Wrangler Drive, Suite 100 Coppell, Texas 75019, hereinafter referred to as “Tenant |
|
| May 15, 2014 |
EX-10.17 Exhibit 10.17 September 27, 2010 ZS Pharma, Inc. 1120 South Freeway Fort Worth, TX 76104 Attention: Alvaro Guillem Chief Executive Officer Jeffrey Keyser Chief Operating Officer 1. This agreement (the “Agreement”) confirms the engagement (the “Engagement’) of Salem Partners LLC (“Salem Partners”) on an exclusive basis as financial advisor to ZS Pharma, Inc. (the “Company”) in connection w |
|
| May 15, 2014 |
EX-4.1 Exhibit 4.1 FORM OF COMMON STOCK CERTIFICATE Number CS- INCORPORATED UNDER THE LAWS OF Shares THE STATE OF DELAWARE Common Stock February 5, 2008 ZS PHARMA, INC. THIS CERTIFIES THAT is the record holder of shares of the Common Stock of ZS Pharma, Inc. hereinafter designated the “Corporation,” par value $0.001 per share, transferable on the share register of the Corporation by the holder, in |
|
| May 15, 2014 |
Registration Statement - FORM S-1 Form S-1 Table of Contents As filed with the Securities and Exchange Commission on May 14, 2014. |
|
| May 15, 2014 |
LICENSE RESTRUCTURING AGREEMENT ZS PHARMA, INC. HEMOCLEANSE, INC. UOP LLC EX-10.11 Exhibit 10.11 LICENSE RESTRUCTURING AGREEMENT BETWEEN ZS PHARMA, INC. HEMOCLEANSE, INC. AND UOP LLC THIS AGREEMENT, dated as of December 19, 2011, is made between ZS Pharma, Inc., a corporation organized and existing under the laws of the State of Delaware, (“ZS Pharma”), HemoCleanse, Inc., a corporation organized and existing under the laws of the State of Indiana, (“HemoCleanse”) and UO |
|
| May 15, 2014 |
EX-10.16 Exhibit 10.16 SUBLEASE This Sublease (this “Sublease”) is entered into this 18th day of October, 2013 (the “Effective Date”) between InB: Hauser Pharmaceutical Services, Inc., a Delaware corporation (“Sublessor”), and ZS Pharma, Inc., a Delaware corporation (“Sublessee”). WHEREAS, Sublessor and Clear Creek Business Park LLC, a Colorado limited liability company (“Landlord”), entered into |
|
| May 15, 2014 |
ZS PHARMA, INC. FORM OF INVENTION ASSIGNMENT AND CONFIDENTIALITY AGREEMENT EX-10.10 Exhibit 10.10 ZS PHARMA, INC. FORM OF INVENTION ASSIGNMENT AND CONFIDENTIALITY AGREEMENT This Invention Assignment and Confidentiality Agreement (“Agreement”) is entered into as of the date of the last signature below and shall be effective as of , 20 , by and between ZS Pharma, Inc., having an address of 508 Wrangler Drive, Suite 100, Coppell, Texas, 75019, its subsidiaries, affiliates, |
|
| May 15, 2014 |
ZS PHARMA, INC. FORM OF NONSTATUTORY STOCK OPTION GRANT NOTICE (FOURTH AMENDED STOCK INCENTIVE PLAN) EX-10.5 Exhibit 10.5 ZS PHARMA, INC. FORM OF NONSTATUTORY STOCK OPTION GRANT NOTICE (FOURTH AMENDED STOCK INCENTIVE PLAN) ZS Pharma, Inc. (the “Company”), pursuant to its Fourth Amended Stock Incentive Plan, as may be amended from time to time (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject |
|
| May 15, 2014 |
ZS PHARMA, INC. FORM OF INCENTIVE STOCK OPTION GRANT NOTICE (FOURTH AMENDED STOCK INCENTIVE PLAN) Exhibit 10.4 ZS PHARMA, INC. FORM OF INCENTIVE STOCK OPTION GRANT NOTICE (FOURTH AMENDED STOCK INCENTIVE PLAN) ZS Pharma, Inc. (the “Company”), pursuant to its Fourth Amended Stock Incentive Plan, as may be amended from time to time (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of |
|
| May 15, 2014 |
A LICENSE AGREEMENT ZS PHARMA, INC. UOP LLC EX-10.12 Exhibit 10.12 A LICENSE AGREEMENT BETWEEN ZS PHARMA, INC. AND UOP LLC THIS AGREEMENT, dated as of December 19, 2011, is made between ZS Pharma, Inc., a corporation organized and existing under the laws of the State of Delaware, (“LICENSEE”), and UOP LLC, a limited liability company organized and existing under the laws of the State of Delaware, United States of America (“UOP”). WHEREAS, A |
|
| May 14, 2014 |
CORRESP May 14, 2014 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Attention: Jeffrey P. Riedler Re: ZS Pharma, Inc. Draft Registration Statement on Form S-1 Confidentially Submitted April 4, 2014 CIK No. 0001459266 Ladies and Gentlemen: Set forth below are the responses of ZS Pharma, Inc. (the “Company”) to the comments contained |
|
| April 4, 2014 |
Confidential Draft Registration Statement Confidential Draft Submission No. 1 submitted to the Securities and Exchange Commission on April 4, 2014. This draft registration statement has not been filed publicly with the Securities and Exchange Commission and all information contained herein remains confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. |
